United Therapeutics Corporation (UTHR) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Silver Spring, MD, アメリカ. 現CEOは Martine A. Rothblatt.
UTHR を有する IPO日 1999-06-17, 1,305 名の正社員, に上場 NASDAQ Global Select, 時価総額 $25.36B.
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with chronic and life-threatening diseases, particularly pulmonary hypertension and related conditions. The company's commercial portfolio includes Remodulin, Tyvaso, Orenitram, and Adcirca for treating pulmonary arterial hypertension, as well as Unituxin for high-risk neuroblastoma. United Therapeutics maintains an active pipeline of innovative treatments including gene therapies, advanced drug delivery systems, and next-generation formulations, supported by strategic partnerships with leading medical device and pharmaceutical companies. Headquartered in Silver Spring, Maryland, the company operates globally to address significant unmet medical needs in pulmonary hypertension and oncology.
